Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,616 across all filing types
Latest filing 2026-06-01 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
关于股票交易被实施其他风险警示相关事项的进展公告
Regulatory Filings Classification · 86% confidence The document is an exchange-mandated monthly progress update on remediation measures following a negative internal control audit opinion and the imposition of a risk warning under Shenzhen Stock Exchange listing rules. It is an ongoing compliance announcement rather than a standalone financial report, management change, dividend notice, or similar. It does not include substantive financial statements nor is it merely announcing the publication of a different report. This is best classified as a general regulatory announcement (fallback category).
2026-06-01 Chinese
关于股票交易异常波动的公告
Regulatory Filings Classification · 85% confidence The document is a public announcement by Shenzhen Stock Exchange-listed company ST Haiwang regarding abnormal stock trading fluctuations, including details of price movements, internal checks, and risk warnings. It is not an AGM material, financial report, management change, capital transaction, or any other specific category; rather, it is a general regulatory announcement under exchange rules. Therefore, it falls under the fallback category 'Regulatory Filings' (RNS).
2026-06-01 Chinese
关于股票交易异常波动的公告
Regulatory Filings Classification · 92% confidence The document is an official announcement by Shenzhen Haier Bio Engineering Co. regarding abnormal fluctuations in its stock trading over consecutive days, providing explanations and risk warnings as required by the Shenzhen Stock Exchange. It does not contain financial statements, meeting materials, voting results, or any specific form filings (e.g., 10-K, IR). It serves as a regulatory disclosure notice under exchange rules, fitting the fallback category for miscellaneous regulatory announcements (RNS).
2026-05-26 Chinese
第十届董事局第九次会议决议公告
Board/Management Information Classification · 85% confidence The document is an official announcement of the board of directors’ meeting resolutions (第十届董事局第九次会议决议公告), detailing the convening of the board meeting, proposals considered, and voting results. This falls under Board/Management Information.
2026-05-22 Chinese
关于股票交易严重异常波动暨风险提示公告
Regulatory Filings Classification · 88% confidence The document is an official announcement under Shenzhen Stock Exchange rules regarding severe abnormal stock price fluctuations and associated risk warnings. It does not present financial statements, voting results, dividends, or detailed audit data, nor is it a capital or M&A update. It is a general regulatory disclosure, making it a Regulatory Filing (RNS).
2026-05-20 Chinese
关于为控股子公司提供担保实施情况的公告
Regulatory Filings Classification · 80% confidence The document is a corporate announcement (“公告”) by Shenzhen Haiwang Bioengineering Co., Ltd. detailing guarantees provided by the parent company for its subsidiaries’ bank credit facilities. It does not contain financial statements or substantive periodical results, nor is it a meeting presentation, proxy statement, or management report. Rather, it is a general regulatory disclosure of contingent liabilities (guarantees), which does not neatly fit into any more specific category. Therefore, under the fallback classification, it is a Regulatory Filing (RNS).
2026-05-20 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.